Leap Therapeutics (NASDAQ:LPTX) Cut to “Hold” at Baird R W

by · The Markets Daily

Baird R W cut shares of Leap Therapeutics (NASDAQ:LPTX – Free Report) from a strong-buy rating to a hold rating in a research note published on Wednesday,Zacks.com reports.

Several other analysts also recently weighed in on LPTX. HC Wainwright downgraded Leap Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday. Robert W. Baird lowered Leap Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $9.00 to $1.25 in a report on Wednesday.

Get Our Latest Report on LPTX

Leap Therapeutics Price Performance

Leap Therapeutics stock opened at $0.56 on Wednesday. Leap Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $4.79. The firm has a fifty day moving average price of $2.74 and a two-hundred day moving average price of $2.73. The firm has a market cap of $21.46 million, a price-to-earnings ratio of -0.29 and a beta of 0.17.

Institutional Investors Weigh In On Leap Therapeutics

Hedge funds have recently made changes to their positions in the stock. Valence8 US LP bought a new position in Leap Therapeutics during the third quarter valued at about $48,000. HighTower Advisors LLC bought a new stake in shares of Leap Therapeutics during the third quarter valued at approximately $65,000. HB Wealth Management LLC increased its position in shares of Leap Therapeutics by 103.2% during the fourth quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after purchasing an additional 26,150 shares during the period. Marshall Wace LLP raised its stake in shares of Leap Therapeutics by 268.2% in the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after purchasing an additional 58,094 shares in the last quarter. Finally, Exome Asset Management LLC bought a new position in Leap Therapeutics in the third quarter worth $264,000. Institutional investors own 30.46% of the company’s stock.

About Leap Therapeutics

(Get Free Report)

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.

Featured Articles